

Advances in Upper Gastrointestinal Malignancies Research

Guest Editor



Prof. Ulrich Ronellenfitsch

Department of Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale), Halle (Saale), Germany

Ulrich.Ronellenfitsch@uk-halle.de

Message from the Guest Editor

Dear Colleagues,

The treatment of upper gastrointestinal malignancies, i.e. tumors of the esophagus and stomach, has seen remarkable advances over the past few decades. Chemotherapy, immunotherapy, targeted therapy with antibodies or biologicals, and radiotherapy have expanded the available therapeutic options beyond mere surgical resection. The latter, however, remains the only potentially curative modality for many upper gastrointestinal malignancies. Surgical techniques have also undergone landmark developments in recent years, with minimally invasive or robotic approaches now being a mainstay in many settings. The ideal combination and temporal sequence of treatments is being evaluated in clinical trials and is constantly evolving. Researchers from all involved fields collaborate on trials, which nowadays increasingly include patient-centered endpoints beyond survival, such as quality of life and functional outcomes. The ultimate aim of these trials is to improve the wellbeing and outcome of patients with upper gastrointestinal malignancies.

Frontiers in Bioscience-Landmark will publish a Special Issue titled Advances in Upper Gastrointestinal Malignancies Research. The aim of this special issue is to cover all facets of research relating to upper gastrointestinal malignancies, with a focus on potential clinical implications. Submissions containing original pre-clinical and clinical research, short communications, meta-analyses and review articles are all welcome.

I invite you to submit your articles before the deadline indicated above.

Prof. Ulrich Ronellenfitsch

Guest Editor

Submission Deadline: **31 October 2022**

Submission: <https://www.imrpress.com/journal/FBL>

Science Citation Index Expanded: **4.009** (2020)

Contact us: FBL@imrpress.com